Agenus Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 6.84 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 307.94M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, a programmed death receptor-1 (PD-1) blocking antibody; AGEN1181, a human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody that is in Phase 2 trials in metastatic colorectal cancer (mCRC), pancreatic cancer, and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFβ TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in clinical development; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monoclonal antibodies; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; and AGEN1884. The company operates under the Agenus, MiNK, Prophage, Retrocyte Display, and STIMULON trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., UroGen Pharma Ltd., Gilead Sciences, Inc., Incyte Corporation, and Merck Sharp & Dohme. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
Details
| Name | Agenus Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 81 |
| Founded | 1994 |
| Ipo Date | 2000-02-04 |
| Ceo | Garo Armen |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | US00847G8042 |
| Cusip | 00847G804 |
| Cik | 0001098972 |
| Sic | 2836 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Dr. Jennifer S. Buell Ph.D. | Director and President and Chief Executive Officer of MiNK Therapeutics |
| Dr. Garo H. Armen Ph.D. | Founder, Interim Chief Financial Officer, Principal Financial Officer, Chief Executive Officer and Executive Chairman |
| Dr. Steven J. O'Day M.D., Ph.D. | Chief Medical Officer |
| Craig Winter | Chief Information Officer |
| Zack Armen | Vice President of Investor Relations and Corporate Development |
| Stefanie Perna-Nacar | Chief Communications and Government Relations Officer |
| Tracy Mazza Clemente | Chief People Officer |
| Dr. Todd Jude Yancey M.D. | Member of Advisory Board and Chief Strategic Advisor |
| Dr. Robin G. Taylor M.B.A., Ph.D. | Chief Commercial Officer |
| Dr. Kamel Djazouli M.D. | Head of Medical Affairs |
Contact
| Address | 3 Forbes Road, Lexington, Massachusetts 02421-7305, United States |
| Phone | 781 674 4400 |
| Website | https://www.agenusbio.com |